EMCDDA–Europol 2017 Annual Report on the implementation of Council Decision 2005/387/JHA
This report presents the key activities performed by the EMCDDA and Europol in 2017 and the results of the implementation of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances, including new psychoactive substances notified in 2017...
European Drug Report
European Drug Report 2018: Trends and Developments
The Trends and Developments report presents a top-level overview of the drug phenomenon in Europe, covering drug supply, use and public health problems as well as drug policy and responses. Together with the online Statistical Bulletin and 30 Country Drug Reports, it makes up the 2018 European Drug...
Fentanils and synthetic cannabinoids: driving greater complexity into the drug situation — an update from the EU Early Warning System
In this update from the EU Early Warning System, the EMCDDA aims to provide insights into what is happening with new psychoactive substances in Europe, based on data from the agency’s early warning and risk-assessment activities. This report covers the period from January 2016 until December 2017.
Report on the risk assessment of 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA) in the framework of the Council Decision on new psychoactive substances
This publication presents the data and findings of the risk assessment on 1-(4-Cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (CUMYL-4CN-BINACA), carried out by the extended Scientific Committee of the EMCDDA on 7-8 November 2017. On the basis of the Risk Assessment Report — and on...
EMCDDA–Europol Joint Report on a new psychoactive substance: 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3-carboxamide (CUMYL-4CN-BINACA)
In March 2017, the EMCDDA and Europol examined the available information on the new psychoactive substance 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)indazole-3- carboxamide, commonly known as CUMYL-4CN-BINACA, through a joint assessment. The two organisations launched a data collection on this...
Perspectives on Drugs (PODs)
Synthetic cannabinoids in Europe (Perspectives on drugs)
Synthetic cannabinoids represent the largest group of substances currently monitored in Europe by the EMCCDA through the EU Early Warning System. Current knowledge on these substances and trends in production, availability, use and harms are presented in this analysis. Part of the ‘Perspectives on...